NCT06282549View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension

Active, not recruitingOBSERVATIONAL
Enrollment

1,219

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Essential Hypertension
Interventions
DRUG

Telmisartan/Amlodipine/Chlorthalidone(Truset)

Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/12.5 mg or Telmisartan/Amlodipine/Chlorthalidone 80/5/25 mg

Trial Locations (5)

42835

Daegu Veterans Hospital, Daegu

46996

Busan Veterans Hospital, Busan

62284

Gwangju Veterans Hospital, Gwangju

05030

Konkuk University Medical Center, Seoul

05368

Veterans Health Service Medical Center, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY